Aims-To produce and characterise a monoclonal antibody specific for 0-acetylated sialomucin and to assess its use in immunohistochemistry on a panel of normal and diseased intestinal tissue samples. Methods-Mouse monoclonal antibodies were developed following immunisation with highly purified human colonic mucin. One of these showed strong binding to mucin throughout the normal colon with relative lack of binding to colon cancer tissue. The binding epitope of MMM-17 was then characterised by screening for agglutination activity against a panel of human and animal erythrocytes and by assessment of its binding to a range of normal and chemically treated slot blotted mucins. Further immunohistochemical studies were then performed on formalin fixed, normal, and diseased human intestinal samples. Results-Binding of MMM-17 to slot blotted human colonic mucin was reduced by 38 (SD 14%) (n = 4) by alkali treatment of the mucin, sequential alkali and sialidase treatment completely abolished binding. Sialidase treatment alone, however, caused only an 11 (11%) reduction in binding. MMM-17 failed to agglutinate any human, rabbit, rat or mouse erythrocytes. These findings were compatible with specificity of MMM-17 for sialomucins 0-acetylated at the C-7 or C-8 positions on the sialic acid. Strong staining by MMM-17 was found in all goblet cells throughout all 40 normal colonic and rectal samples studied, but staining was absent in seven of 13 colorectal carcinomas. Normal duodenum (n = 16) and normal ileum (n = 3) all showed occasional positive goblet cells. The normal gastric antral mucosa was generally negative B MMM-17, but in all of 15 cases of gastritis with intestinal metaplasia the metaplastic glands were strongly positive for MMM-17.
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Conchuion-Monoclonal antibody has specificity for 0-acetylated sialomucins and its binding depends both on the position of 0-acetylation and on the adjacent oligosaccharide structure. Preliminary studies using the antibody on archival tissue samples support the previous reports of reduced 0-acetylation in colon cancer demonstrated by indirect histochemistry and show the neo-formation of 0-acetylated sialomucin in intestinal metaplasia in the stomach.
(7Clin Pathol 1993; 46:323-329) Human colonic mucin is heavily sialylated. This increases the charge of the mucin and is important in conferring resistance to degradation by glycosidases as sialic acid needs to be removed by sialidases before exoglycosidases can further degrade the oligosaccharides.' Much of the sialic acid in the human colon is 0-acetylated at the C7, 8, or 9 positions2-4 which considerably increases its resistance to sialidase. 5 6 The 0-acetylation of colonic sialomucins has been shown histochemically before by showing that, whereas colonic mucin is normally only lightly stained by the periodic acid Schiff (PAS) procedure, prior treatment with alkali, which will remove 0-acetyl groups, causes a large increase in PAS staining. Biochemical confirmation of this evidence has been provided by comparative histochemical and biochemical investigations.,8 Further investigations using histochemicall9 and biochemical6 '°techniques have shown that normal colonic mucus contains di-O-acetylated (C8,C9 and C7,C9) or tri-O-acetylated (C7, C8,C9) sialomucins. Although 0-acetylation at C4 was inferred from histochemical techniques,7 subsequent biochemical studies have failed to show C4 0-acetylated sialic acids in human mucins" and this reflects the difficulty in interpreting the ingenious but complex histochemical tests for 0-acetylation.
Decreased 0-acetylation of sialomucins is a common early feature of malignant and premalignant epithelial disorders, particularly in the colon. It has been demonstrated, using both histochemical and biochemical techniques, in colorectal cancer,'0 12 in ulcerative colitis,3 '3 and in colonic adenoma. '4 The availability of an antibody with specificity for 0-acetylated sialomucin would therefore have considerable potential for the study of changes in mucin in malignant and premalignant gastrointestinal disease. Several monoclonal antibodies to normal'5 '7 and neoplastic '8 " 
ELISA FOR DETECTION OF ANTI-MUCIN ANTIBODY
ELISA plates (Dynatech, Billingshurst, Sussex) were coated with human colonic mucin, prepared as before, about 10 pg protein/ml in 100 ,ul 0-05M carbonate/bicarbonate buffer (pH 9 5) , by incubation at 4°C for 16 hours. The plates were washed in 0-01M phosphate buffered saline (pH 7A4), blocked with 125 ul 0-5% bovine serum albumin (BSA) and 0-5% Tween 20 in PBS (PBS/BSA/Tween) for 2 hours at 37°C, washed three times with 0 05% Tween 20 in PBS (PBS/Tween) and 100 pl culture supernatant fluid added for 2 hours at 37°C. The plates were then washed three times with PBS/Tween, 100 p1 1 in 500 peroxidase conjugated rabbit anti-mouse immunoglobulin (Dako, High Wycombe, England) added and incubated for 2 hours at 37°C. After five washes with PBS/Tween, peroxidase activity was detected using 100 pl o-phenylene diamine(OPD)/hydrogen peroxide as substrate (04 mg/ml OPD, 04 ul/ml 30% hydrogen peroxide in 0-05M phosphate/citrate buffer, pH 5 0); after 6 minutes at room temperature the reaction was stopped by the addition of 100 pl 4M sulphuric acid and the absorption at 490 nm read with a CLS microplate reader (Cambridge Life Sciences, Cambridge, England).
To study the ability of bovine submaxillary mucin and its desialylated derivative (desialylated by treatment with 0-05M sulphuric acid for 1 hour at 80°C) to inhibit binding of antibody to human colonic mucin, ELISA plates were coated with purified mucin as described above, blocked with PBS/BSA/Tween, and then 50 pl of 1 in 5 culture supematant fluid was added followed immediately by 50 ul potential inhibitor and the standard ELISA procedure continued. 2 For mild acid hydrolysis blots were treated with 0 05M sulphuric acid for 1 hour at 80°C and then blocked and stained as described before. Immunoblotting was also performed on samples of bovine (BSM) and equine submaxillary mucin (ESM) (kindly supplied by Dr A P Corfield, Department of Medicine, University of Bristol, England). As an alternative procedure mucin was also incubated in solution with either 0-1M NaOH or 0-05M~~~~~'~7 Y7 H,SO4, before blotting on to nitrocellulose and proceeding to incubation with MMM-17 as described before.
Results
Screening of 50 culture supernatant fluids from fusion products yielded a culture, MMM-17, which when expanded produced an antibody with affinity for purified colonic mucin as demonstrated by ELISA. Screening with IgM and IgG subclass specific antiimmunoglobulins showed the antibody to be IgGI. Monitoring of gel filtration fractions from crude mucin applied to a Superose 6 column showed that the antibody reacted with the initial mucin fractions (fig 1) with no reactivity with lower molecular weight material.
The only normal mucosa which consistently showed strong positive staining was the colon (n = 36) in which all goblet cells were stained without exception (fig 2) . These included nine samples of ascending and descending colon from patients with a range of known ABO blood groups and secretor status. Gall-bladder columnar epithelium stained consistently albeit less strongly (n = 4). Mucin producing cells in other sites, including nasal mucosa (n = 2), submandibular salivary gland (n = 3), normal gastric antrum (n = 7), duodenal (n = 16) and ileal (n = 3) mucosa, were either unstained or showed weak focal positivity (table 1) . Consistent positive staining was observed in metaplastic epithelium in the stomach (n = 15) and oesophagus (n = 3) (fig 3) . Seven out of 13 carcinomata of the colon or rectum showed complete lack of staining ( fig 2) ; in the remaining six occasional goblet cells were positive. These results are summarised in table 1. No agglutination of human, Wistar rat, BALB/c and C57B1 mouse or New Zealand rabbit erythrocytes was observed under any of the conditions tested.
Mild acid hydrolysis of blotted normal human colonic mucin almost abolished 82 (SD 15) % reduction binding of MMM-17 ( fig 4) and caused more than a 95% reduction in binding of LFA, although WGA binding was slightly increased (table 2), suggesting that there was no significant removal of mucin from the nitrocellulose. When mucin was incubated with dilute acid before application on to the nitrocellulose the ability to bind MMM-17 was similarly abolished, with no effect on WGA binding, again indicating that the effect of the acid was not simply to remove the mucin from the nitrocellulose.
When blots were treated with sialidase alone there was no significant reduction in MMM-17 binding (11 (11%) The effect of bovine submaxillary mucin on the ability of MMM-17 to bind to colonic mucin was investigated with an ELISA inhibition technique, where it was found that BSM inhibited such binding by 60% at 1 ,ug/ml; desialylated BSM was much less effective, requiring a concentration of 10 ,ug/ml for comparable inhibition (fig 5) . Equine submaxillary mucin, which does not bind MMM-17, did not inhibit the binding of the antibody to colonic mucin. 
Discussion
The monoclonal antibody MMM-1 7 is specific for human colonic mucin and is effective for use in immunohistochemistry on fixed tissue. Prevention of MMM-17 binding to mucin by prior mild acid hydrolysis of the mucin suggests that its binding epitope contains sialic acid, fucose, or ester sulphate, all of which would be removed by this process. The finding that there is only partial reduction in MMM-1 7 staining following alkali treatment, whereas the combination of alkali and sialidase results in total loss of binding, suggests that the epitope involves those sialic acids or sialylated oligosaccharides which are 0-acetylated, but that binding is not totally dependent on the 0-acetyl groups themselves. The additional finding that sialidase alone has no effect on binding implies that only those sialic acid residues that are 0-acetylated are involved in binding and that they differ from those that are not 0-acetylated, either in the nature of their linkage to the oligosaccharide side chain or the nature of the side chain to which they are linked. The lack of agglutinating activity for human erythrocytes is consistent with specificity for 0-acetylated sialomucin as human erythrocyte sialic acids are not 0-acetylated." 23 Rabbit and rodent red blood cells are known to contain sialic acid residues 0-acetylated at the C-9 position,23 so the lack of agglutination of these cells implies that MMM-17 does not recognise mono-9-O-acetylated sialic acid, as found on these cells.
The This is, we believe, the first description of a monoclonal antibody with affinity for some types of 0-acetylated sialomucins. Monoclonal antibodies have been produced against 0-acetylated sialic residues on gangliosides25 2b but these have not been shown to react with sialomucins,25 probably because sialomucins and gangliosides have different configurations of the oligosaccharide side chain.
The striking positivity seen with MMM-17 in all 15 of the gastric tissue samples with intestinal metaplasia samples studied shows that the sialylated mucin known to be secreted by these cells27 has a similar 0-acetylation to that of normal colonic mucin. The colorectal tumours that have been studied so far with this antibody have shown either a complete lack of MMM-17 staining or only patchy staining, thus supporting the reduction in 0-acetylation of colon cancer sialomucin that has previously been shown using indirect histochemical techniques.
There is considerable interest in the alterations in sialylation that may occur in mucin and cell surface glycoproteins in malignant disease and there is evidence that such alterations may correlate with altered metastatic potential.528 29 The role of changes in 0-acetylation of tumour sialic acids is unknown but deserves further study. Reduction in 0-acetylation of sialic acids has been reported in colon cancer,'0 12 14 adenomatous colonic polyps,14 and in ulcerative colitis,'3 30 but these studies have all relied on indirect histochemical techniques which can sometimes be difficult to interpret. Monoclonal antibodies specific for 0-acetylated sialomucins should facilitate further studies of these changes.
